Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care

被引：2
|
作者：
Parperis, Konstantinos [1 ,2 ]
机构：
[1] Univ Cyprus, Sch Med, Div Rheumatol, Internal Med, CY-1678 Nicosia, Cyprus
[2] Univ Arizona, Coll Med Phoenix, Med, Phoenix, AZ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷 / 12期
关键词：
gout; NSAIDs; treatment;
D O I：
10.1136/annrheumdis-2019-216643
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E202 / E202
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of ambulatory care management of primary spontaneous pneumothorax: an open-label, randomised controlled trial
    Luengo-Fernandez, Ramon
    Landeiro, Filipa
    Hallifax, Rob
    Rahman, Najib M.
    THORAX, 2022, 77 (09) : 913 - 918
  • [22] High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
    Dhooria, Sahajal
    Chaudhary, Shivani
    Sehgal, Inderpaul Singh
    Agarwal, Ritesh
    Arora, Siddhant
    Garg, Mandeep
    Prabhakar, Nidhi
    Puri, Goverdhan Dutt
    Bhalla, Ashish
    Suri, Vikas
    Yaddanapudi, Lakshmi Narayana
    Muthu, Valliappan
    Prasad, Kuruswamy Thurai
    Aggarwal, Ashutosh Nath
    EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (02)
  • [23] Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018
    Coenen, Samuel
    van Der Velden, Alike W.
    Cianci, Daniela
    Goossens, Herman
    Bongard, Emily
    Saville, Benjamin R.
    Gobat, Nina
    de Paor, Muireann
    Leven, Margareta
    Verheij, Theo J.
    Butler, Christopher C.
    BRITISH JOURNAL OF GENERAL PRACTICE, 2020, 70 (696): : E444 - E449
  • [24] Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study
    Andrés Martin
    Kathleen Koenig
    George M. Anderson
    Lawrence Scahill
    Journal of Autism and Developmental Disorders, 2003, 33 : 77 - 85
  • [25] Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study
    Martin, A
    Koenig, K
    Anderson, GM
    Scahill, L
    JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2003, 33 (01) : 77 - 85
  • [26] ORAL LOW-DOSE PULSE METHOTREXATE (MTX) IN PRIMARY SCLEROSING CHOLANGITIS (PSC) - AN OPEN LABEL TRIAL
    MOSES, FM
    STAMM, CP
    LARSEN, BL
    SHAH, RB
    BREWER, TG
    HEPATOLOGY, 1991, 14 (04) : A195 - A195
  • [27] Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT) a pragmatic, superiority, open-label, randomised controlled trial
    Kyle, Simon
    Siriwardena, Niroshan
    Espie, Colin A.
    Yang, Yaling
    Petrou, Stavros
    Ogburn, Emma
    Begum, Nargis
    Maurer, Leonie F.
    Robinson, Barbara
    Gardner, Caroline
    Lee, Victoria
    Armstrong, Stephanie
    Pattinson, Julie
    Mort, Sam
    Temple, Eleanor
    Harris, Victoria
    Yu, Ly-Mee
    Bower, Peter
    Aveyard, Paul
    LANCET, 2023, 402 (10406): : 975 - 987
  • [28] A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
    Van Linschoten, R.
    Jansen, F.
    Pauwels, R.
    Smits, L.
    Atsma, F.
    Kievit, W.
    de Jong, D.
    de Vries, A.
    Boekema, P.
    West, R.
    Bodelier, A.
    Gisbertz, I.
    Wolfhagen, F.
    Romkens, T.
    Lutgens, M.
    van Bodegraven, A.
    Oldenburg, B.
    Pierik, M.
    Russel, M.
    de Boer, N.
    Mallant-Hent, R.
    ter Borg, P.
    van der Meulen-de Jong, A.
    Jansen, J.
    Jansen, S.
    Tan, A.
    van der Woude, C. J.
    Hoentjen, F.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 655 - 658
  • [29] Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial
    Kissinger, Patricia
    Muzny, Christina A.
    Mena, Leandro A.
    Lillis, Rebecca A.
    Schwebke, Jane R.
    Beauchamps, Laura
    Taylor, Stephanie N.
    Schmidt, Norine
    Myers, Leann
    Augostini, Peter
    Secor, William E.
    Bradic, Martina
    Carlton, Jane M.
    Martin, David H.
    LANCET INFECTIOUS DISEASES, 2018, 18 (11): : 1251 - 1259
  • [30] Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial
    Kluck, Viola
    Jansen, Tim L. Th A.
    Janssen, Matthijs
    Comarniceanu, Antoaneta
    Efde, Monique
    Tengesdal, Isak W.
    Schraa, Kiki
    Cleophas, Maartje C. P.
    Scribner, Curtis L.
    Skouras, Damaris B.
    Marchetti, Carlo
    Dinarello, Charles A.
    Joosten, Leo A. B.
    LANCET RHEUMATOLOGY, 2020, 2 (05): : E270 - E280
12345